Published in J Med Econ on January 01, 2010
Evaluating the administration costs of biologic drugs: development of a cost algorithm. Health Econ Rev (2014) 0.79
Health expenditure comparison of extended-release metoprolol succinate and immediate-release metoprolol tartarate. Clinicoecon Outcomes Res (2012) 0.75
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 5.26
Global epidemiology of hepatitis B virus. J Clin Gastroenterol (2004) 4.48
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood (2008) 4.02
Expanding the evidence base in transplantation: the complementary roles of randomized controlled trials and outcomes research. Transplantation (2008) 3.43
Warfarin pharmacogenetics. Pharmacotherapy (2008) 2.50
Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann Intern Med (2002) 2.43
A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genet Med (2010) 2.40
Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. Value Health (2008) 2.31
A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics (2010) 2.19
Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers. Appl Health Econ Health Policy (2014) 2.02
Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement. J Comp Eff Res (2012) 1.91
Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy (2010) 1.83
Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda. BMC Health Serv Res (2009) 1.82
An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost (2008) 1.76
Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics. Med Decis Making (2013) 1.70
Design, implementation, and first-year outcomes of a value-based drug formulary. J Manag Care Spec Pharm (2015) 1.67
The use, safety and cost of bariatric surgery before and after Medicare's national coverage decision. Ann Surg (2011) 1.63
A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Ann Emerg Med (2012) 1.58
Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. J Gastroenterol Hepatol (2007) 1.58
Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics (2010) 1.55
A risk-benefit analysis of factor V Leiden testing to improve pregnancy outcomes: a case study of the capabilities of decision modeling in genomics. Genet Med (2012) 1.52
Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Making (2010) 1.45
Economic outcome of cardiac CT-based evaluation and standard of care for suspected acute coronary syndrome in the emergency department: a decision analytic model. Acad Radiol (2011) 1.45
The timing of elective colectomy in diverticulitis: a decision analysis. J Am Coll Surg (2004) 1.45
Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. Pharmacogenet Genomics (2006) 1.44
Optimizing CAD diagnosis in China with CT angiography. J Cardiovasc Comput Tomogr (2009) 1.43
Patients' experience and outcomes after laparoscopic adjustable gastric banding in Washington state. Surg Obes Relat Dis (2012) 1.42
Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet Med (2012) 1.39
Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support. BMC Bioinformatics (2010) 1.32
Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med (2005) 1.27
Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. Value Health (2009) 1.22
Global eradication of measles: an epidemiologic and economic evaluation. J Infect Dis (2011) 1.19
The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med (2004) 1.19
Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics (2010) 1.19
Cost effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda. PLoS One (2011) 1.19
A cost-effectiveness analysis of intraoperative cholangiography in the prevention of bile duct injury during laparoscopic cholecystectomy. J Am Coll Surg (2003) 1.18
Prioritization in comparative effectiveness research: the CANCERGEN Experience. Med Care (2012) 1.17
Return of incidental findings in genomic medicine: measuring what patients value--development of an instrument to measure preferences for information from next-generation testing (IMPRINT). Genet Med (2013) 1.16
The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health (2008) 1.16
Estimating the costs of induced abortion in Uganda: a model-based analysis. BMC Public Health (2011) 1.13
Economic analyses of human genetics services: a systematic review. Genet Med (2005) 1.10
Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany. J Med Econ (2012) 1.09
A review of selected patient-generated outcome measures and their application in clinical trials. Value Health (2003) 1.07
Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc (2003) 1.07
Estimating the effect of changes in body mass index on health state preferences. Pharmacoeconomics (2002) 1.06
Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer (2008) 1.06
Implications of Part D for mentally ill dual eligibles: a challenge for Medicare. Health Aff (Millwood) (2006) 1.02
The ISPOR Good Practice Modeling Principles--a sensible approach: be transparent, be reasonable. Value Health (2003) 1.01
Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties. Bioorg Med Chem (2012) 1.00
Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK. Pharmacoeconomics (2006) 0.99
Potential cost-effectiveness of universal access to modern contraceptives in Uganda. PLoS One (2012) 0.98
Stakeholder perspectives on a risk-benefit framework for genetic testing. Public Health Genomics (2010) 0.98
Which antimicrobial impregnated central venous catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use. Am J Infect Control (2003) 0.97
Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. Diabetes Care (2011) 0.97
The economics of genomic medicine: insights from the IOM Roundtable on Translating Genomic-Based Research for Health. JAMA (2013) 0.97
The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007). Contemp Clin Trials (2012) 0.97
Expectations, validity, and reality in pharmacogenetics. J Clin Epidemiol (2009) 0.96
Managed care in the genomics era: assessing the cost effectiveness of genetic tests. Am J Manag Care (2003) 0.96
Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res (2013) 0.96
Navigational bronchoscopy with biopsy versus computed tomography-guided biopsy for the diagnosis of a solitary pulmonary nodule: a cost-consequences analysis. J Bronchology Interv Pulmonol (2012) 0.95
An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis. J Gastroenterol Hepatol (2009) 0.95
In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenet Genomics (2005) 0.95
Use of maximal sterile barriers during central venous catheter insertion: clinical and economic outcomes. Clin Infect Dis (2004) 0.95
Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis. J Med Econ (2012) 0.94
Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol (2004) 0.93
A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications. Drug Metab Rev (2008) 0.93
A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics (2008) 0.93
Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer. Drugs (2008) 0.92
Economic incentives for evidence generation: promoting an efficient path to personalized medicine. Value Health (2013) 0.92
The clinical and economic consequences of screening young men for genital chlamydial infection. Sex Transm Dis (2003) 0.91
Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. Am J Manag Care (2004) 0.91
Health state preference assessment in diabetic peripheral neuropathy. Pharmacoeconomics (2002) 0.91
Cytochrome p450 enzyme polymorphism frequency in indigenous and native american populations: a systematic review. Community Genet (2008) 0.91
Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests. Am J Manag Care (2006) 0.90
Fondaparinux for isolated superficial vein thrombosis of the legs: a cost-effectiveness analysis. Chest (2011) 0.90
Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. J Med Econ (2011) 0.89
Assessing the cost-effectiveness of measles elimination in Uganda: local impact of a global eradication program. J Infect Dis (2011) 0.89
Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis. J Med Econ (2012) 0.89
Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study. Diabetes Ther (2012) 0.89
Preference values associated with stage III colon cancer and adjuvant chemotherapy. Qual Life Res (2010) 0.89
Health economic evaluation of non-melanoma skin cancer and actinic keratosis. Pharmacoeconomics (2004) 0.88
Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals. J Manag Care Pharm (2009) 0.87
Examining the BMI-mortality relationship using fractional polynomials. BMC Med Res Methodol (2011) 0.87
Long-term survival in patients with severe acute respiratory distress syndrome and rescue therapies for refractory hypoxemia*. Crit Care Med (2014) 0.86
Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting. Curr Med Res Opin (2011) 0.86
The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma. Cancer (2005) 0.86